Table 2. Promoter hypermethylation in NSCLC tissue (n=117).
| Any methylation PMR>0% | High methylation PMR≥4% | |
|---|---|---|
| APC* | 64 (57%) | 43 (38%) |
| BVES | 47 (40%) | 27 (23%) |
| CCND2* | 63 (56%) | 33 (29%) |
| CDH1 | 48 (41%) | 7 (6%) |
| CDH13 | 29 (25%) | 13 (11%) |
| CDKN2A | 30 (26%) | 30 (26%) |
| CDKN2B | 5 (4%) | 0 (0%) |
| DAPK1 | 24 (21%) | 7 (6%) |
| FANCF | 1 (1%) | 1 (1%) |
| FHIT | 1 (1%) | 0 (0%) |
| GSTP1 | 2 (2%) | 2 (2%) |
| IGFBP3 | 14 (12%) | 2 (2%) |
| IGSF4 | 26 (22%) | 3 (3%) |
| KCNH5 | 39 (33%) | 22 (19%) |
| KCNH8 | 22 (19%) | 12 (10%) |
| MGMT | 12 (10%) | 5 (4%) |
| MLH1 | 1 (1%) | 1 (1%) |
| OPCML | 18 (15%) | 16 (14%) |
| P14 | 0 (0%) | 0 (0%) |
| PCSK6 | 11 (9%) | 3 (3%) |
| PTEN | 1 (1%) | 1 (1%) |
| PTGS2 | 1 (1%) | 0 (0%) |
| RARB | 58 (50%) | 36 (31%) |
| RASSF1 | 35 (30%) | 35 (30%) |
| RUNX | 25 (21%) | 25 (21%) |
| SOCS3 | 0 (0%) | 0 (0%) |
| TMS1 | 15 (13%) | 9 (8%) |
*
112 LC Blocks for APC and CCND2